retatrutide (LY3437943) / Eli Lilly - LARVOL DELTA

EFFECTS OF INCRETIN-BASED THERAPIES ON KIDNEY OUTCOMES IN OBESE PATIENTS WITHOUT DIABETES (ISN-WCN 2026) - "Consistent findings across frequentist and Bayesian analyses strengthened result robustness.Conclusion Among obese adults without diabetes, Retatrutide produced the largest improvement in eGFR, while Semaglutide and Retatrutide most effectively reduced UACR. Incretin-based therapies may confer renal benefits beyond glycemic control, supporting further evaluation of dual GLP-1/GIP agonists in nondiabetic obesity-related kidney disease."

Clinical • Cardiovascular • Diabetes • Diabetic Nephropathy • Genetic Disorders • Inflammation • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • RAS

Retatrutide Enhances Weight Loss in Female Mice and Preserves Muscle Mass, Strength, and Mitochondrial Efficiency (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders

Weight Loss with Tirzepatide and Retatrutide Is Associated with Changes in Food Preference and Multiple Metabolic Benefits in the Free Choice Diet–Induced Obese Hamster Model (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders • Obesity

Obese Rhesus Monkeys Recapitulate Human Efficacy Profiles of Semaglutide, Bimagrumab, and Retatrutide (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Metabolic Disorders • Obesity

Oral Delivery of Semaglutide, Tirzepatide, and Retatrutide Formulated in Polymerized Ursodeoxycholic Acid (pUDCA) Nanoparticles (NP) (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Metabolic Disorders

CT-SY17-1.5: Symposium - Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results) (ADA 2026) - No abstract available

Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Results of 1st Phase 3 Study of Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist in Patients with T2D (TRANSCEND-T2D-1) (ADA 2026) - No abstract available

Clinical • P3 data • Metabolic Disorders • Type 2 Diabetes Mellitus

Results of 1st Phase 3 Study of Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist in Patients with Obesity (TRIUMPH-1) (ADA 2026) - No abstract available

Clinical • P3 data • Metabolic Disorders • Obesity

The TRANSCEND-T2D Phase 3 clinical trial program is evaluating the safety and efficacy of retatrutide for the treatment of adults with type 2 diabetes across three global registrational trials. (Eli Lilly Press Release) - "The program, which began in 2024, has enrolled more than 2,050 participants and additional results are anticipated over the next year."

P3 data • Type 2 Diabetes Mellitus

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial (cnbc) - "The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, meeting the study’s main goal. Patients started the trial with an A1c in the range of 7% to 9.5%, and were not taking other diabetes medications...Retatrutide also met the study’s second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug."

P2 data • Type 2 Diabetes Mellitus

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions. (PubMed, Liver Int) - "However, resmetirom received FDA approval in March 2024 for the treatment of MASH, and semaglutide (Wegovy) was granted accelerated FDA approval in August 2025 for MASH with moderate-to-advanced fibrosis. Additional agents such as tirzepatide and retatrutide remain in late-stage clinical development...As such, future strategies involving the LPI/GPR55 axis must focus on hepatic-specific GPR55 modulation using selective ligands and advanced delivery systems, mitigating off-target effects. This review elucidates the mechanistic role of the LPI/GPR55 axis, combining the role of MBOAT7 in the pathophysiology of metabolic-associated liver disease."

Journal • Review • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • GPR55

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. (PubMed, Endocrinol Diabetes Metab) - "Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head-to-head trials."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

GZBF: Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Hudson Biotech

New P2 trial • Genetic Disorders • Obesity

Retatrutide in type 2 diabetes mellitus and obesity: an overview. (PubMed, Expert Rev Clin Pharmacol) - "Increased frequency of mild-to-moderate gastrointestinal adverse events (mainly nausea, vomiting, constipation and diarrhea) was reported in participants on the highest retatrutide doses, likely due to rapid dose escalation and higher starting dose. These promising effects on glycemic control, weight loss and emerging pleiotropic actions merit further investigation."

Journal • Review • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) (clinicaltrials.gov) - P3 | N=537 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) (clinicaltrials.gov) - P3 | N=10000 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Nephrology • Obesity • Renal Disease

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. (PubMed, Obesity (Silver Spring)) - "Retatrutide demonstrates multiple metabolic benefits in both mouse and hamster models. Our preclinical setting will help to assess the efficacy of novel therapies targeting obesity and MASH."

Journal • Preclinical • Genetic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Umbrella Labs Announces GLP-3R, The New Research Designation For Retatrutide, To Support High Rigor Tri-Receptor Endocrine Signaling Bench Science (Yahoo Finance) - "Umbrella Labs is aligning its tri-receptor peptide offering under the GLP-3R designation to minimize ambiguity in ordering language, labeling, and internal recordkeeping, while preserving established identifiers such as LY-3437943 and retatrutide for cross referencing...Umbrella Labs is addressing this risk by standardizing retatrutide as GLP-3R within its research catalog, making the GLP-3R name the primary procurement label while retaining retatrutide and LY-3437943 as secondary identifiers for continuity."

Clinical • Obesity • Type 2 Diabetes Mellitus

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. (PubMed, Int J Obes (Lond)) - "Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide, exhibit significant anti-obesity effects in MC4R KO mice. These results suggest that GLP-1 analogs may provide an effective treatment option for patients with MC4R-POMC pathway deficiencies. Moreover, the efficacy of these drugs in MC4R KO mice aligns with clinical studies, indicating that MC4R KO mice serve as a reliable animal model for obesity research."

Journal • Genetic Disorders • Inflammation • Obesity • LEP • MC4R

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. (PubMed, Cardiol Rev) - "Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism...A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults...No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65-1.14). In conclusion, incretin-based polyagonists were associated with significant weight reduction and improved metabolic outcomes compared to placebo."

Journal • Retrospective data • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Alteogen is trying to stretch the obesity drug playbook beyond weekly injections, saying preclinical data suggest its once-monthly candidate can deliver weight loss comparable to Eli Lilly’s retatrutide. (Korea Biomedical Review) - "In an obese rat pharmacodynamics study, the company said its once-monthly candidate produced weight loss comparable to Eli Lilly’s once-weekly subcutaneous retatrutide, which has shown 29 percent weight loss in clinical trials and has been watched as a potential step up from marketed drugs like Wegovy (semaglutide) and Mounjaro (tirzepatide). Alteogen said earlier animal pharmacokinetics work showed a long half-life and sustained drug exposure."

Preclinical • Obesity

Retatrutide: Data from P3 TRIUMPH-3 trial (NCT05882045) for obesity in 2026 (Eli Lilly) - Q4 2025 Results

P3 data • Obesity

Retatrutide: Regulatory submission for obesity in 2026 (Eli Lilly) - Q4 2025 Results

Filing • Obesity

Retatrutide: Data from P3 TRIUMPH-1 trial (NCT05929066) for obesity in 2026 (Eli Lilly) - Q4 2025 Results: Data from P3 TRIUMPH-2 trial (NCT05929079) for obesity in 2026

P3 data • Obesity

Retatrutide: Primary completion and completion of P3 trial (NCT07035093) for obesity in Sep 2027 (Eli Lilly) - Q4 2025 Results

Trial completion date • Trial primary completion date • Obesity